MPN Expert On How New Guidelines Will Affect Disease Treatment

The NCCN updated their guidelines on treatment for myeloproliferative neoplasms (MPNs), outlining diagnosis, treatment and care strategies.
BY KATIE KOSKO @Katie_Kosko
PUBLISHED: NOVEMBER 15, 2016
The National Comprehensive Cancer Network (NCCN) recently issued new guidelines for myeloproliferative neoplasms (MPNs). They specifically outline diagnosis, treatment and supportive care strategies for myelofibrosis (MF). 

Rubin Mesa, M.D., professor of Hematology at the Mayo Clinic in Arizona, explained the changes and what lies ahead in the treatment of MPNs during a presentation at the 34th Annual Chemotherapy Foundation Symposium™.

In an interview with CURE, Mesa provided an overview of the new NCCN guidelines and what they mean for MPNs are managed and treated.

Can you give a recap of your talk on the evolving guidelines for MPNs?

We focused first on diagnosis, prognosis and symptom burden, validating and endorsing the criteria for diagnosis, the already recognized prognostic scores in these diseases, as well as the importance of symptom assessment.

The guidelines have really begun first with the therapy for myelofibrosis to clarify risk assessment and disease burden in patients. We then stratify really by the risk itself and then stratify patients between those that we observe, such as low-risk asymptomatic; those that we consider for medical therapy with Jakafi (ruxolitinib); as well as trying to clarify where we can consider clinical trials, which really occurs all along the way. Also, the guidelines address the importance of stem cell transplantation, in particular for intermediate 1 with high-risk molecular features, intermediate 2 and high-risk in good transplant candidates and crucially for individuals that are evolving toward acute leukemia.

I hope these new guidelines will provide greater clarity and uniformity of care for myelofibrosis in the U.S.

Will these guidelines also be updated to include recommendations for essential thrombocythemia (ET) and polycythemia vera (PV) as well?

That is correct. There is a lot to tackle to begin with, so we anticipate the next step will include treatment guidelines for PV and ET. And then subsequently, guidelines for the less common MPNs of hypereosinophilic syndrome, systemic mast cell disease, etc.

Additionally, the myelofibrosis guidelines will be routinely updated as we have potentially other drugs that are currently in the pipeline. If they’re approved, the guidelines will be updated very shortly thereafter, so that we can see where those best fit.

How will these guidelines be used in clinical practice?

We hope the guidelines will be useful. We recognize the challenges involved in trying to keep track of so many different diseases — just keeping abreast of the number of new drugs approved in myeloma alone would be enough to be a full-time job for anyone.

The guidelines also address some of the key — and more challenging — decision points. Sometimes, for patients for whom there is uncertainty about appropriate treatment, that can be a time to bounce options off individuals who focus on the disease or utilize platforms such as the American Society of



Talk about this article with other patients, caregivers, and advocates in the Myelodysplastic syndrome CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
Expert Discusses Important Updates in MPN Treatment
In an interview with CURE  Mesa, director, UT Health San Antonio Cancer Center, shed light on these recent updates in PV and ET, and discussed the proper therapeutic management of these diseases.
Expert Gives an Overview of New Drugs to Treat AML
For the past four decades, there have been few advances in the treatment field of acute myeloid leukemia (AML). However, in the year 2017, there have been four new drugs approved by the FDA to treat the disease, with even more promising agents in the pipeline.
So You Have Cancer, Eat the Donut
Cancer survivors generally work very hard to be healthy after a diagnosis. This article gives permission to enjoy life and have a balanced attitude toward healthy living.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Filling an Unmet Need in MDS Treatment
Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies at Moffitt Cancer Center, discusses an unmet need in the treatment of myelodysplastic syndrome (MDS).
Andrew Schorr on How Journalism Led Him to Patient Advocacy
Andrew Schorr, founder of Patient Power and Patient Empowerment and 2016 MPN Hero, discusses how his background in journalism led him to patient advocacy.
x
//For side ad protocol